These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22294598)

  • 41. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, Nov. 3-4, 2011, Rockville, MD.
    Khan AS; Lubiniecki A; King KE
    PDA J Pharm Sci Technol; 2012; 66(6):502-11. PubMed ID: 23183646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel endogenous simian retroviral integrations in Vero cells: implications for quality control of a human vaccine cell substrate.
    Sakuma C; Sekizuka T; Kuroda M; Kasai F; Saito K; Ikeda M; Yamaji T; Osada N; Hanada K
    Sci Rep; 2018 Jan; 8(1):644. PubMed ID: 29330501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative detection of RT activity by PERT assay: feasibility and limits to a standardized screening assay for human vaccines.
    André M; Morgeaux S; Fuchs F
    Biologicals; 2000 Jun; 28(2):67-80. PubMed ID: 10885614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine.
    Tatalick LM; Gerard CJ; Takeya R; Price DN; Thorne BA; Wyatt LM; Anklesaria P
    Vaccine; 2005 Apr; 23(20):2628-38. PubMed ID: 15780446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ensuring the safety of vaccine cell substrates by massively parallel sequencing of the transcriptome.
    Onions D; Côté C; Love B; Toms B; Koduri S; Armstrong A; Chang A; Kolman J
    Vaccine; 2011 Sep; 29(41):7117-21. PubMed ID: 21651935
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction/activation and detection of occult viral agents present in mammalian cells.
    Schüpbach J
    Dev Biol (Basel); 2001; 106():425-37; discussion 465-75. PubMed ID: 11761258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of vaccines, interferons and cell substrates for pestivirus contamination.
    Audet SA; Crim RL; Beeler J
    Biologicals; 2000 Mar; 28(1):41-6. PubMed ID: 10799055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative study of influenza virus replication in Vero and MDCK cell lines.
    Youil R; Su Q; Toner TJ; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Kiseleva I; Shaw AR; DiStefano D
    J Virol Methods; 2004 Sep; 120(1):23-31. PubMed ID: 15234806
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experience with vero cells at Pasteur Mérieux Connaught.
    Montagnon BJ; Vincent-Falquet JC; Saluzzo JF
    Dev Biol Stand; 1999; 98():137-40; discussion 167. PubMed ID: 10494966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 Influenza A Virus in Cells.
    Wen F; Li L; Zhao N; Chiang MJ; Xie H; Cooley J; Webby R; Wang PG; Wan XF
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidate vaccine strains.
    Zhou J; Yang F; Yang J; Ma L; Cun Y; Song S; Liao G
    Hum Vaccin Immunother; 2017 Jan; 13(1):111-116. PubMed ID: 27648636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses.
    Zanotto C; Paganini M; Elli V; Basavecchia V; Neri M; De Giuli Morghen C; Radaelli A
    Vaccine; 2005 Sep; 23(39):4745-53. PubMed ID: 15950328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of MDCK cells for production of live attenuated influenza vaccine.
    Liu J; Shi X; Schwartz R; Kemble G
    Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
    Barrett PN; Terpening SJ; Snow D; Cobb RR; Kistner O
    Expert Rev Vaccines; 2017 Sep; 16(9):883-894. PubMed ID: 28724343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages.
    Hu W; Zhang H; Han Q; Li L; Chen Y; Xia N; Chen Z; Shu Y; Xu K; Sun B
    Vaccine; 2015 Jan; 33(2):374-81. PubMed ID: 25448099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Citrate-mediated disaggregation of rotavirus particles in RotaTeq vaccine.
    Peterson SE; Wang S; Ranheim T; Owen KE
    Antiviral Res; 2006 Feb; 69(2):107-15. PubMed ID: 16325930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a Vero cell-derived influenza whole virus vaccine.
    Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
    Dev Biol Stand; 1999; 98():101-10; discussion 111. PubMed ID: 10494963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.
    Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
    Wien Klin Wochenschr; 1999 Mar; 111(5):207-14. PubMed ID: 10226351
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New technologies and challenges of novel virus detection.
    Khan AS; Ma H; Taliaferro LP; Galvin TA; Shaheduzzaman S
    PDA J Pharm Sci Technol; 2014; 68(6):661-6. PubMed ID: 25475641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs.
    Govorkova EA; Kodihalli S; Alymova IV; Fanget B; Webster RG
    Dev Biol Stand; 1999; 98():39-51; discussion 73-4. PubMed ID: 10494958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.